天目药业 (600671.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

79.9x

Market Cap

CNY 2.42B

MomentumView details →

1D Return

−3.27%

YTD Return

+26.40%

RSI (14)

55.7

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

79.9x

Market Cap

CNY 2.42B

RSI (14)

55.7

MomentumView details →

1D Return

−3.27%

YTD Return

+26.40%

ProfitabilityView details →

Gross Margin

51.04%

Net Margin

8.02%

EBITDA Margin

17.37%

ROE (TTM)

22.14%

ROA (TTM)

3.52%

Asset Turnover

0.45x

GrowthView details →

Revenue YoY

−15.71%

EPS YoY

−45.59%

FCF YoY

+58.17%

Revenue CAGR 3Y

+24.81%

EPS CAGR 3Y

+15.58%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

2.53x

Current Ratio

0.84x

Quick Ratio

0.70x

Div Yield

—

Div Rate

—

Div Growth 1Y

+1700.07%

Financials snapshotView financials →

Revenue (TTM)

203.85M

Net Income (TTM)

16.34M

Op. CF (TTM)

2.01M

Latest newsMore news →

Tianmu Pharmaceutical announced its first-half 2026 results: net profit attributable to shareholders was 6.3022 million yuan, down 38.50% year-on-year.8d ago

Similar companies

TYK Medicines, Inc02410.HK Organon & Co.OGN Tong Ren Tang Technologies Co. Ltd.01666.HK Impact Therap-b07630.HK 神奇制药600613.SH Grifols, S.A.GRFS Find similar companies →

Latest newsMore news →

Tianmu Pharmaceutical announced its first-half 2026 results: net profit attributable to shareholders was 6.3022 million yuan, down 38.50% year-on-year.8d ago